By combining the immunohistochemical staining results for SOD3 and CAV1 with the mRNA expression levels of SELM, IGFBP3, PLAC9, and PLAU, we aimed to provide a comprehensive understanding of the molecular characteristics and potential therapeutic targets associated with the fibroblast component in PAAD. This evidence concerns the gene CAV1 and pancreatic adenocarcinoma.